Recombinant Human TTK protein

中文名： TTK蛋白激酶(TTK)重组蛋白
别名： TTK；MPS1；MPS1L1；Dual specificity protein kinase TTK

货号: PA1000-7960

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	TTK
Uniprot No	P33981
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-857aa
氨基酸序列	MESEDLSGRELTIDSIMNKVRDIKNKFKNEDLTDELSLNKISADTTDNSGTVNQIMMMANNPEDWLSLLLKLEKNSVPLSDALLNKLIGRYSQAIEALPPDKYGQNESFARIQVRFAELKAIQEPDDARDYFQMARANCKKFAFVHISFAQFELSQGNVKKSKQLLQKAVERGAVPLEMLEIALRNLNLQKKQLLSEEEKKNLSASTVLTAQESFSGSLGHLQNRNNSCDSRGQTTKARFLYGENMPPQDAEIGYRNSLRQTNKTKQSCPFGRVPVNLLNSPDCDVKTDDSVVPCFMKRQTSRSECRDLVVPGSKPSGNDSCELRNLKSVQNSHFKEPLVSDEKSSELIITDSITLKNKTESSLLAKLEETKEYQEPEVPESNQKQWQSKRKSECINQNPAASSNHWQIPELARKVNTEQKHTTFEQPVFSVSKQSPPISTSKWFDPKSICKTPSSNTLDDYMSCFRTPVVKNDFPPACQLSTPYGQPACFQQQQHQILATPLQNLQVLASSSANECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEEMKYVLGQLVGLNSPNSILKAAKTLYEHYSGGESHNSSSSKTFEKKRGKK
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于TTK重组蛋白的3篇参考文献示例(注：以下为模拟内容，非真实存在的文献)：

1. **文献名称**：《重组TTK蛋白激酶的表达及其在细胞周期调控中的作用》

**作者**：李明等

**摘要**：研究通过大肠杆菌系统成功表达并纯化重组TTK蛋白，验证其激酶活性，并发现其通过磷酸化特定底物参与有丝分裂检查点调控，为癌症治疗提供潜在靶点。

2. **文献名称**：《TTK重组蛋白晶体结构解析与抑制剂筛选》

**作者**：Smith J, et al.

**摘要**：利用昆虫细胞表达系统获得高纯度TTK重组蛋白，解析其三维晶体结构，结合虚拟筛选技术鉴定出新型小分子抑制剂，为抗肿瘤药物开发奠定基础。

3. **文献名称**：《基于重组TTK蛋白的功能性抗体开发与肿瘤诊断应用》

**作者**：Wang Y, et al.

**摘要**：通过哺乳动物细胞表达重组TTK蛋白，制备特异性单克隆抗体，证实其在多种癌症组织中的高表达，提出其作为肿瘤诊断生物标志物的潜力。

---

以上示例涵盖重组TTK蛋白的表达体系(如大肠杆菌、昆虫细胞)、功能研究(激酶活性、细胞周期调控)及转化应用(药物筛选、诊断标志物)，反映了该领域的主要研究方向。实际文献检索建议通过PubMed或Web of Science以“TTK recombinant protein”、“MPS1 kinase expression”等关键词查询。

背景信息

**Background of TTK Recombinant Protein**

TTK, also known as Threonine-Tyrosine Kinase or MPS1 (Mitotic Kinase Monopolar Spindle 1), is a serine/threonine kinase critical for regulating cell cycle progression, particularly during mitosis. It plays a key role in the spindle assembly checkpoint (SAC), a surveillance mechanism that ensures accurate chromosome segregation by delaying anaphase until all chromosomes are properly attached to the mitotic spindle. Dysregulation of TTK is linked to genomic instability, a hallmark of cancer, making it a potential therapeutic target.

Recombinant TTK protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification to ensure high purity and functional activity. This engineered protein retains the kinase activity and structural features of native TTK, enabling researchers to study its biochemical properties, interactions, and role in mitosis. It is widely used in *in vitro* assays to screen for small-molecule inhibitors, investigate signaling pathways, and explore mechanisms underlying SAC dysfunction.

In cancer research, TTK overexpression has been observed in various malignancies, including breast, lung, and colorectal cancers, correlating with poor prognosis. Inhibiting TTK kinase activity disrupts SAC function, leading to premature mitotic exit and cell death in cancer cells with chromosomal abnormalities. Consequently, TTK inhibitors are being developed as anticancer agents, with several candidates in preclinical or early clinical trials.

Additionally, recombinant TTK aids structural biology studies, facilitating the determination of its 3D conformation and ATP-binding site. These insights guide rational drug design to improve inhibitor specificity and reduce off-target effects. Despite its promise, challenges remain, such as balancing efficacy with toxicity and overcoming resistance mechanisms. Overall, TTK recombinant protein serves as a vital tool for advancing both basic research and therapeutic innovation in oncology.

(Word count: 298)